|
tips |
publicēšana |
3 |
Žurnāls |
Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
31 |
Žurnāls |
Zhang Y, Xu QA, Trissel LA, Gilbert DL. Physical and chemical stability of methotrexate sodium, cytarabine, and hydrocortisone sodium succinate in Elliott’s B solution. Hosp Pharm 1996 ; 31: 965-970. |
59 |
Žurnāls |
Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
62 |
Žurnāls |
Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125. |
73 |
Žurnāls |
Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159. |
81 |
Žurnāls |
Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678. |
84 |
Žurnāls |
Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499. |
91 |
Žurnāls |
Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210. |
93 |
Žurnāls |
Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188. |
99 |
Žurnāls |
Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
132 |
Žurnāls |
Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184. |
169 |
Žurnāls |
Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363. |
182 |
Žurnāls |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60. |
186 |
Žurnāls |
Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022. |
198 |
Žurnāls |
Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520. |
211 |
Žurnāls |
Strom JG, Miller SW. Stability and compatibility of methylprednisolone sodium succinate and cimetidine hydrochloride in 5% dextrose injection. Am J Hosp Pharm 1991 ; 48: 1237-1241. |
215 |
Žurnāls |
Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426. |
244 |
Žurnāls |
Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913. |
248 |
Žurnāls |
Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304. |
249 |
Žurnāls |
Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
251 |
Žurnāls |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
253 |
Žurnāls |
Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528. |
288 |
Žurnāls |
Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962. |
299 |
Žurnāls |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
300 |
Žurnāls |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
301 |
Žurnāls |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
307 |
Žurnāls |
Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799. |
317 |
Žurnāls |
Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362. |
334 |
Žurnāls |
Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992. |
335 |
Žurnāls |
Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406. |
336 |
Žurnāls |
Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409. |
384 |
Žurnāls |
Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632. |
397 |
Žurnāls |
Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126. |
398 |
Žurnāls |
Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557. |
402 |
Žurnāls |
Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821. |
479 |
Žurnāls |
Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966. |
491 |
Žurnāls |
Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184. |
492 |
Žurnāls |
Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189. |
631 |
Žurnāls |
Das Gupta V, Stewart KR. Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion. J Parenter Sci Technol 1985 ; 39: 145-148. |
738 |
Žurnāls |
Gardella LA, Kesler H, Amann A, Carter JE. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978 ; 35: 581-584. |
739 |
Žurnāls |
Cradock JC, Kleinmann LM, Rahman A. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. Am J Hosp Pharm 1978 ; 35: 402-406. |
905 |
Žurnāls |
Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017. |
921 |
Žurnāls |
Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292. |
939 |
Žurnāls |
Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170. |
1028 |
Žurnāls |
Cheung YW, Vishnuvajjala BR, Flora KP. Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures. Am J Hosp Pharm 1984 ; 41: 1802-1806. |
1035 |
Žurnāls |
Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132. |
1057 |
Žurnāls |
Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207. |
1085 |
Žurnāls |
Irving HD, Burbridge BE. Incompatibility of contrast agents with intravascular medications. Radiology 1989 ; 173: 91-92. |
1200 |
Žurnāls |
Chaudry IA, Bruey KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742. |
1228 |
Žurnāls |
Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381. |
1232 |
Žurnāls |
Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236. |
1259 |
Žurnāls |
Jhunjhunwala VP, Bhalla HL. Compatibility of aminophylline with hydrocortisone sodium succinate or dexamethasone sodium phosphate in 5% dextrose injection. Am J Hosp Pharm 1981 ; 38: 900-901. |
1315 |
Žurnāls |
Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297. |
1410 |
Žurnāls |
Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145. |
1415 |
Žurnāls |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74. |
1423 |
Žurnāls |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
1490 |
Žurnāls |
Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254. |
1496 |
Žurnāls |
Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428. |
1625 |
Žurnāls |
Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321. |
1661 |
Žurnāls |
Trissel LA, King KM, Zhang Y, Wood AM. Physical and chemical stability of methotrexate, cytarabine, and hydrocortisone in Elliott’s B Solution for intrathecal use. J Oncol Pharm Practice 2002 ; 8: 27-32. |
1662 |
Žurnāls |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37. |
1712 |
Žurnāls |
Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233. |
1713 |
Žurnāls |
Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315. |
1721 |
Žurnāls |
Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72. |
1754 |
Žurnāls |
Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244. |
1803 |
Žurnāls |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85. |
1822 |
Žurnāls |
Trissel LA, Seanz C. Physical compatibility of antithymocyte globulin (rabbit) with heparin sodium and hydrocortisone sodium succinate. Am J Health-Syst Pharm 2003 ; 60: 1650-1652. |
1888 |
Žurnāls |
Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48. |
1925 |
Žurnāls |
Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519. |
1944 |
Žurnāls |
Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774. |
1964 |
Žurnāls |
Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785. |
1982 |
Žurnāls |
Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837. |
2001 |
Žurnāls |
Rigge DC, Jones MF. Shelf lives of aseptically prepared medicines - stability of hydrocortisone sodium succinate in PVC and non-PVC bags and in polypropylene syringes. J Pharm Biomed Anal 2005 ; 38: 332-336. |
2087 |
Žurnāls |
Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20. |
2090 |
Žurnāls |
Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196. |
2109 |
Žurnāls |
Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75. |
2247 |
Žurnāls |
Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278. |
2262 |
Žurnāls |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
2269 |
Žurnāls |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
2354 |
Žurnāls |
Das Gupta V, Ling J. Stability of hydrocortisone sodium succinate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2000 ; 4, 5: 396-397. |
3012 |
Žurnāls |
Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220. |
3152 |
Žurnāls |
Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
3216 |
Žurnāls |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18 |
3249 |
Žurnāls |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
3254 |
Žurnāls |
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
3267 |
Laboratorija |
Lipomed Laboratories Dacarbazine Lipomed - Summary of Product Characteristics Lipomed 2011 |
3372 |
Žurnāls |
Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166. |
3379 |
Žurnāls |
Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524. |
3408 |
Žurnāls |
Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21. |
3540 |
Laboratorija |
Heparin sodium - Summary of Product Characteristics. Wockhardt 2010 |
3545 |
Laboratorija |
Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009 |
3564 |
Laboratorija |
Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012 |
3571 |
Žurnāls |
Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47. |
3580 |
Laboratorija |
Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016 |
3588 |
Laboratorija |
Vancomycine (Vancocin®) - Résumé des caractéristiques du produit Sandoz 2011 |
3594 |
Laboratorija |
Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013 |
3604 |
Laboratorija |
Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012 |
3605 |
Laboratorija |
Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit Lipomed 2010 |
3728 |
Žurnāls |
Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291. |
3766 |
Žurnāls |
Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165. |
3767 |
Žurnāls |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172. |
3824 |
Žurnāls |
Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98 |
3827 |
plakāts |
Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015 |
3828 |
plakāts |
Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015 |
3829 |
plakāts |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015 |
3838 |
Laboratorija |
Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007 |
3879 |
Žurnāls |
Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332. |
3964 |
Žurnāls |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33. |
3976 |
Žurnāls |
Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218 |
4055 |
Žurnāls |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
4145 |
Žurnāls |
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
4154 |
Laboratorija |
Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018 |
4254 |
Žurnāls |
D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40 |
4319 |
Žurnāls |
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337. |
4411 |
Žurnāls |
Wilder A.G, Foushee J.A, Fox L.M, Navalle J, Wright A.M, Greer M.A. Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions. Int J Pharm Compound 2020 ;24,3:238-241. |
4433 |
Žurnāls |
Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485. |
4465 |
Žurnāls |
Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148 |
4528 |
Žurnāls |
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61 |
4550 |
Žurnāls |
Semark, A.J, Venkatesh, K, McWhinney B.C, Pretorius, C, Roberts, J.A, Cohen J, Venkatesh B. The compatibility of a low concentration of hydrocortisone sodium succinate with selected drugs during a simulated Y-site administration. Crit Care Resusc 2013 ;15, 1: 63–66. |
4603 |
Žurnāls |
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234. |
4641 |
Žurnāls |
Zanon D, Selmin F, Centin G, Maximova N, Casiraghi A, Minghetti P. Stability of high concentrated triple intrathecal therapy for pediatrics and mitigation strategies. Eur J Pharm Sci 2021 ;167: 106039. |
4698 |
Žurnāls |
Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022 |
4742 |
Žurnāls |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255. |
4776 |
Žurnāls |
Tomczak S, Chmielewski, M, Szkudlarek J, Jeliinska A. Antiemetic Drugs Compatibility Evaluation with Paediatric Parenteral Nutrition Admixtures. Pharmaceutics 2023 ; 15: 2143. |
4801 |
Žurnāls |
Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1: |
4837 |
Žurnāls |
De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087. |